Related Experiment Videos
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease
Insights
Pravastatin is a cost-effective option for secondary prevention of coronary artery disease (CAD) in men. The cost per life-year saved ranges from $7,124 to $12,665, comparing favorably with other medical interventions.
Area of Science:
- Cardiovascular Medicine
- Health Economics
Background:
- Coronary Artery Disease (CAD) poses a significant public health challenge, necessitating effective secondary prevention strategies.
- Elevated low-density lipoprotein cholesterol (LDL-C) is a key risk factor in patients with established CAD.
- Pravastatin has demonstrated plaque regression in clinical trials, suggesting potential benefits in secondary prevention.
Purpose of the Study:
- To evaluate the cost-effectiveness of pravastatin for secondary prevention of CAD in male patients.
- To determine the cost per life-year saved associated with pravastatin therapy.
Main Methods:
- A projected risk model was developed using data from 445 male patients with established CAD and moderately elevated LDL-C.
- Results from two placebo-controlled plaque regression trials (Pravastatin Limitation of Atherosclerosis in the Coronary Arteries and Pravastatin, Lipids, and Atherosclerosis in the Carotids) were utilized.
- Framingham Heart Study data informed mortality risk projections post-myocardial infarction (MI).
- A Markov process estimated life-years saved, and decision analysis calculated costs.
Main Results:
- The estimated cost per life-year saved with pravastatin ranged from $7,124 to $12,665, varying by patient-risk profile.
- These costs are considered favorable when compared to other established medical interventions for secondary CAD prevention.
Conclusions:
- Pravastatin represents a cost-effective intervention for secondary prevention of coronary artery disease in male patients.
- The favorable cost-effectiveness supports the use of pravastatin in managing patients with established CAD and elevated LDL-C.
Abstract:
This study analyzed the cost-effectiveness of pravastatin in secondary prevention of coronary artery disease (CAD). The projected risk model in 445 male patients with established CAD and moderately elevated serum low-density lipoprotein cholesterol used results data from 2 placebo-controlled plaque regression trials: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries and Pravastatin, Lipids, and Atherosclerosis in the Carotids. Framingham Heart Study data were used to project the risk of mortality 10 years after myocardial infarction (MI) for incremental male patients in the placebo group who had MI. A Markov process was used to estimate life-years saved, and decision analysis was used to estimate cost. Depending on the patient-risk profile, the midrange estimated cost per life-year saved with pravastatin in secondary prevention of CAD varied from $7,124 to $12,665, which is favorable compared with other widely accepted medical interventions.